



LKT Laboratories, Inc.

Crizotinib

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lctlabs.com](mailto:getinfo@lctlabs.com)  
Web: [lctlabs.com](http://lctlabs.com)

## Product Information

Product ID C6935

CAS No. 877399-52-5

Chemical Name

Synonym

Formula  $C_{21}H_{22}Cl_2FN_5O$

Formula Wt. 450.34

Melting Point


Purity  $\geq 98\%$

Solubility

Store Temp Ambient

Ship Temp Ambient

**Description** Crizotinib is an inhibitor of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and c-MET, binding competitively to the ATP-binding pocket of kinases. Crizotinib exhibits anticancer chemotherapeutic benefit in the treatment of non-small cell lung cancer (NSCLC) and is currently in clinical trials as a potential treatment for neuroblastoma and other advanced solid tumors. In cellular models, this compound upregulates expression of pro-apoptotic BIM and downregulates expression of anti-apoptotic survivin to induce apoptosis and inhibit cell proliferation.



**Bulk quantities available upon request**

Product ID	Size
C6935	5 mg
C6935	10 mg
C6935	25 mg
C6935	100 mg

**References** Timm A, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. *Am J Health Syst Pharm.* 2013 Jun 1;70(11):943-7. PMID: 23686600.

Okamoto W, Okamoto I, Arai T, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. *Mol Cancer Ther.* 2012 Jul;11(7):1557-64. PMID: 22729845.

Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. *J Thorac Oncol.* 2011 Oct;6(10):1624-31. PMID: 21716144.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.